NERV
Minerva Neurosciences, Inc. NASDAQ Listed Jul 1, 2014$6.12
Mkt Cap $42.8M
52w Low $1.30
43.2% of range
52w High $12.46
50d MA $6.53
200d MA $4.24
P/E (TTM)
-0.2x
EV/EBITDA
-1.1x
P/B
—
Debt/Equity
-0.5x
ROE
208.5%
P/FCF
-0.0x
RSI (14)
—
ATR (14)
—
Beta
-0.21
50d MA
$6.53
200d MA
$4.24
Avg Volume
255.0K
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
1601 Trapelo Road · Burlington, MA 02451 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11, 2026 | AMC | -0.11 | -0.64 | -481.8% | 7.30 | -0.4% | +5.3% | +1.8% | +0.1% | +0.1% | -0.9% | — |
| Nov 5, 2025 | AMC | -0.35 | -0.36 | -2.9% | 3.82 | -0.5% | -4.7% | +1.9% | +2.7% | +4.2% | +0.8% | — |
| Aug 14, 2025 | AMC | -0.95 | -0.43 | +54.7% | 1.80 | +4.4% | +25.0% | +8.4% | -6.1% | +0.4% | +5.2% | — |
| May 13, 2025 | AMC | -1.07 | -0.50 | +53.3% | 1.63 | +4.3% | -5.5% | +1.3% | -3.8% | -3.3% | -4.8% | — |
| Feb 25, 2025 | AMC | -1.05 | -0.56 | +46.7% | 1.79 | -2.2% | -2.2% | -2.9% | -1.8% | -8.4% | +3.3% | — |
| Nov 5, 2024 | AMC | -1.01 | 2.97 | +394.1% | 2.36 | -2.1% | -2.1% | +0.4% | +0.9% | -0.9% | -0.4% | — |
| Aug 6, 2024 | AMC | -0.97 | -1.09 | -12.4% | 2.94 | +1.4% | -2.7% | +3.5% | -2.7% | -0.7% | -2.1% | — |
| May 1, 2024 | AMC | -1.20 | -1.13 | +5.8% | 2.40 | +0.0% | -2.1% | +0.9% | -1.3% | +6.4% | +0.8% | — |
| Feb 22, 2024 | AMC | -0.88 | -1.19 | -35.2% | 7.25 | +11.9% | -5.2% | -1.0% | -58.8% | +1.1% | -5.7% | — |
| Nov 7, 2023 | AMC | -0.77 | -1.03 | -33.8% | 5.26 | -2.9% | -0.4% | -11.8% | -11.3% | -3.4% | +23.0% | — |
| Aug 1, 2023 | AMC | -0.44 | -1.12 | -154.5% | 10.38 | +0.2% | +1.3% | -3.9% | -4.1% | -1.9% | -3.0% | — |
| May 15, 2023 | AMC | -1.63 | -1.31 | +19.6% | 6.44 | -2.2% | -12.4% | +8.3% | +10.1% | -0.3% | +1.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $7.30 | $7.27 | -0.4% | +5.3% | +1.8% | +0.1% | +0.1% | -0.9% |
| Nov 6 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.82 | $3.80 | -0.5% | -4.7% | +1.9% | +2.7% | +4.2% | +0.8% |
| Feb 26 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.79 | $1.75 | -2.2% | -2.2% | -2.9% | -1.8% | -8.4% | +3.3% |
| Nov 6 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $2.36 | $2.31 | -2.1% | -2.1% | +0.4% | +0.9% | -0.9% | -0.4% |
| Aug 7 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $2.94 | $2.98 | +1.4% | -2.7% | +3.5% | -2.7% | -0.7% | -2.1% |
| May 2 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $2.40 | $2.40 | +0.0% | -2.1% | +0.9% | -1.3% | +6.4% | +0.8% |
| Feb 27 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $6.80 | $3.30 | -51.5% | -58.8% | +1.1% | -5.7% | -1.5% | -1.9% |
| Aug 2 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $10.38 | $10.40 | +0.2% | +1.3% | -3.9% | -4.1% | -1.9% | -3.0% |
| May 16 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $6.44 | $6.30 | -2.2% | -12.4% | +8.3% | +10.1% | -0.3% | +1.6% |
| May 2 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.76 | $3.86 | +2.7% | +22.1% | +0.7% | -0.2% | +30.2% | -2.2% |
| Mar 9 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.87 | $1.87 | +0.0% | -3.2% | -7.7% | +3.0% | +3.5% | -2.2% |
| Nov 10 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $3.26 | $3.06 | -6.1% | +4.3% | -1.8% | -8.4% | +12.7% | -4.6% |
| Oct 17 | JMP Securities | Downgrade | Market Outperform → Market Perform | — | $13.43 | $4.43 | -67.0% | -69.5% | -7.1% | -13.7% | -0.3% | -2.8% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.44 | $5.66 | +4.0% | -1.5% | -5.4% | +6.9% | -0.7% | +2.6% |
| Jun 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.36 | $31.60 | +0.8% | -1.8% | -4.9% | -1.1% | -6.1% | +0.3% |
| Dec 19 | H.C. Wainwright | Maintains | Buy → Buy | — | $55.12 | $42.48 | -22.9% | -17.9% | +5.7% | +10.0% | +9.4% | -4.3% |
| Dec 19 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $55.12 | $42.48 | -22.9% | -17.9% | +5.7% | +10.0% | +9.4% | -4.3% |
| Sep 25 | Chardan Capital | Maintains | Buy → Buy | — | $65.68 | $66.48 | +1.2% | +1.3% | -1.1% | -0.5% | -5.3% | -26.3% |
| Sep 18 | William Blair | Maintains | Outperform → Outperform | — | $64.88 | $68.80 | +6.0% | +3.8% | +2.9% | -0.3% | -2.8% | -2.1% |
| May 31 | H.C. Wainwright | Maintains | Buy → Buy | — | $39.52 | $40.40 | +2.2% | +5.5% | +1.9% | -2.4% | -3.5% | -1.4% |
| Mar 6 | Jefferies | Maintains | Buy → Buy | — | $66.40 | $67.60 | +1.8% | +6.0% | -1.7% | +0.0% | -2.3% | +3.0% |
| May 27 | Jefferies | Maintains | Buy → Buy | — | $94.40 | $94.80 | +0.4% | -4.1% | +8.7% | +13.1% | +3.0% | -11.7% |
| Mar 9 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $42.32 | $44.00 | +4.0% | +2.3% | +3.0% | +1.8% | +3.7% | +0.0% |
| Jul 28 | Jefferies | Maintains | Buy → Buy | — | $54.24 | $55.92 | +3.1% | +11.1% | -4.5% | -9.2% | -3.4% | -0.8% |
| Jul 28 | JMP Securities | Maintains | Market Perform → Perform | — | $54.24 | $55.92 | +3.1% | +11.1% | -4.5% | -9.2% | -3.4% | -0.8% |
| Jul 28 | Baird | Maintains | Outperform → Outperform | — | $54.24 | $55.92 | +3.1% | +11.1% | -4.5% | -9.2% | -3.4% | -0.8% |
No insider trades available.
8-K · 2.02
!! High
Minerva Neurosciences, Inc. -- 8-K 2.02: Earnings Results
Minerva Neurosciences reported quarterly earnings results, with detailed financial performance and operational updates available in the accompanying press release exhibit.
May 5
8-K
Unknown — 8-K Filing
This administrative address update for shareholder proposals likely reflects a routine corporate housekeeping change with minimal immediate stock impact, though investors should monitor for any underlying organizational restructuring.
Apr 6
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
The sudden departure of the president and simultaneous elevation of a new executive to dual leadership roles creates uncertainty about strategic direction and may signal internal instability that could impact operational continuity.
Apr 2
8-K
Unknown — 8-K Filing
Minerva's delayed Phase 3 trial start (Q2 2026) for its lead schizophrenia drug pushes commercialization to 2028-2029, extending cash burn and increasing dilution risk for investors betting on near-term regulatory approval.
Mar 11
8-K · 7.01
! Medium
Minerva Neurosciences, Inc -- 8-K 7.01: Regulation FD Disclosure
Minerva Neurosciences will present investor materials on its website, signaling continued engagement with shareholders regarding company developments and financial updates.
Feb 3
Data updated apr 26, 2026 2:42pm
· Source: massive.com